Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Alimatravir · 1 trial · 1 indication
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported.
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE will be reported.
| Arm | Type | Description |
|---|---|---|
| Alimatravir | EXPERIMENTAL | Alimatravir 11 mg will be taken once monthly (qm) |
| Name | Type | Description |
|---|---|---|
| Alimatravir | DRUG | 11 mg tablets taken orally once monthly (qm) for a total of 3 doses |
Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Is confirmed human immunodeficiency virus (HIV)-uninfected * Is a transgender or gender diverse (TGD) person, ie, a person whose gender identity differs from the sex that was assigned at birth * Is on s...
Alimatravir is an investigational small molecule developed by Merck & Company, Inc. (ticker MRK) for HIV. It is currently in Phase 2 clinical development and has not been approved by the FDA. Merck is evaluating it in a study population of transgender and gender diverse individuals on gender-affirming hormone therapy.
Alimatravir is being studied for HIV in transgender and gender diverse individuals who are on gender-affirming hormone therapy and at low likelihood of HIV-1 exposure. It is an investigational agent in Phase 2 testing, so its use remains limited to clinical research rather than routine clinical care.
Alimatravir is developed by Merck & Company, Inc., which trades under the ticker MRK. Merck is running the clinical program for the drug, including the Phase 2 study identified as MK-8527-018. The compound is also referred to in that study by the code MK-8527.
Alimatravir is in Phase 2 clinical development. It is investigational and has not been approved by the FDA. One Phase 2 trial is registered for the drug, and it is listed as not yet recruiting, with a planned enrollment of 80 participants.
Alimatravir is being evaluated in the Phase 2 trial NCT07850609, titled a clinical study of Alimatravir (MK-8527) in transgender and gender diverse individuals on gender-affirming hormone therapy and at low likelihood of HIV-1 exposure. The trial is not yet recruiting and plans to enroll 80 participants aged 18 years and older.
Yes, Alimatravir is also known as MK-8527. The Phase 2 trial NCT07850609 lists the drug under both names, Alimatravir (MK-8527), so searches for either term refer to the same Merck investigational compound being studied in HIV.